Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting

2023-509306-29-00 Gastroesophageal cancer 9 2024-09-26
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting

2023-509307-33-00 Gastroesophageal cancer 9 2024-09-26
A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting

2023-507803-76-00 Peripheral T-Cell Lymphoma 10 2024-09-26
tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting

2023-503316-33-00 patients with a positive status for molecular residual 5 2024-09-26
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu… Recruiting

2023-510203-21-00 locally advanced or metastatic non-small cell lung canc 7 2024-09-24
Regorafenib for recurrent meningioma. A multicenter, randomized phase II study (MIRAGE trial) Recruiting

2024-510954-28-01 grade 1, 2 and 3 meningioma 4 2024-09-23
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors Recruiting

2024-511238-11-00 Ovarian cancer, endometrial cancer, cervical cancer, no 1 2024-09-20
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma Recruiting

2022-501811-14-00 Multiple Myeloma 9 2024-09-20
PREOPANC-5 Recruiting

2023-508707-20-00 Borderline resectable pancreatic cancer (BRPC) 9 2024-09-19
A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl… Recruiting

2022-500800-24-00 Multiple Myeloma 4 2024-09-19
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting

2024-511688-27-00 Myelofibrosis 4 2024-09-19
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, pha… Recruiting

2022-501910-79-01 Ovarian cancer 7 2024-09-18
Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial Recruiting

2024-510576-21-00 Pancreatic cancer 4 2024-09-18
Phase II Study to Assess the Efficacy of Niraparib Rechallenge after Surgery in Ovarian Cancer Patients with Oligometastatic Progression (Th… Recruiting

2023-508258-24-00 Ovarian cancer (OC) with oligometastatic progression (O 4 2024-09-12
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting

2024-515118-42-00 Colorectal cancer 11 2024-09-10
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer Recruiting

2023-504013-68-00 Advanced or Metastatic Prostate Cancer 1 2024-09-06
A Phase I/II Study of AZD5863 in Adult Participants with Advanced or Metastatic Solid Tumors Recruiting

2023-504139-42-00 Advanced or metastatic solid tumors 7 2024-09-06
A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy… Recruiting

2024-511074-80-01 Platinum-resistant high-grade ovarian cancer (PROC) or 7 2024-09-06
Improved Recovery by Iron following Surgery with blood loss, a double-blind multi-centre randomized controlled phase III drug trial (the IRI… Recruiting

2022-502776-22-00 Anemia 5 2024-09-05
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Novo metastatic hormone-sensitive prostate cancer (mHSP 5 2024-09-04
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02